Despite insufficient safety data and close ties to industry, FDA advisors voted to allow pharmacies to dispense unapproved peptide drugs BPC-157, KPV, TB-500, and MOTs-C.
A federal advisory committee has taken its first formal step by allowing pharmacies to manufacture four popular but unapproved peptides. 1 This decision could change how these products circulate in the US supply chain and set a precedent for how the FDA should approach the growing category of self-assembling protein compounds.
At a meeting this week, external advisors narrowly recommended adding BPC-157, KPV, and TB-500 to the list of substances that state-licensed pharmacies can dispense on prescription. Eight members voted in favor, six voted against, and one abstained. A fourth peptide drug, MOTs-C, currently undergoing evaluation for use in obesity and osteoporosis, was approved by seven votes in favor, five against, and two abstentions. The group plans to meet again to review three more peptide drugs.
These recommendations come as regulators and industry struggle to balance conflicting demands: on the one hand, expanding legal access to products that are already widely available without any clinical oversight; on the other, maintaining evidence-based standards for drugs that have not yet undergone human clinical trials.
Peptides are composed of the same molecular building blocks as proteins in the human body, and some of them, including insulin, diabetes injections, and weight-loss injections, have already undergone the full approval process. The substance under review this week has not yet undergone the approval process. Instead, many of these substances are sold online with research use permits, allowing consumers to purchase them for purposes such as muscle recovery and life extension, without the need for physician supervision or standardized dosage information. Analysts estimate the total market for these products at $2–3 billion if the pharmaceuticals receive official approval.
Regulatory issues existed even before this week’s meeting. In 2023, federal officials identified nearly 20 peptides as potentially unsafe and blocked their synthesis. This year, that position began to change, as more than a dozen peptides were reclassified, and some of them now fall under the approval pathway currently under discussion.
For companies following traditional R&D processes, this review is less about individual products and more about the robustness of scientifically sound evaluation. Regulatory officials recommended against expanding the use of customized drugs due to a lack of safety and efficacy data. At the hearing, representatives noted that customized drugs do not require labeling with dosage or risk information and urged sponsors to instead submit formal applications and conduct controlled clinical trials in humans. Approving the sale of unapproved peptide drugs in the absence of relevant data effectively opens a path parallel to the established route that manufacturers have long been required to follow, impacting quality standards, liability risks, and the competitive environment between manufacturers and sponsors of approved drugs.
The committee’s composition exacerbated this tension. Seven of the 14 members were added before the meeting from clinics or companies marketing peptide therapies, and most of those who voted in favor were associated with this industry. “All committee members underwent the same ethics and eligibility review process as all FDA advisory committee members,” said Emily Hilliard, a spokeswoman for the Department of Health and Human Services. However, not all panel members believed this process reflected rigorous scientific principles.
“I’m concerned that we’re reacting to market demands rather than making decisions based on sound science,” said Elizabeth Rebello, a professor at the University of Texas and a member of the commission.¹
The agency is not bound by the recommendations of its advisors and has not yet made a final decision. Whatever decision it makes, it will help clarify the line between legitimately expanding patient access to this drug and circumventing the clinical evidence framework governing the use of other classes of peptide drugs.
Get key insights that will shape the future of pharmaceutical manufacturing and regulatory compliance. Subscribe to Pharmaceutical Technology magazine and stay informed about industry breakthroughs.
Post time: Nov-02-2026